Universidade Federal do Rio de Janeiro Hospital Universitário Clementino Fraga Filho Divisão de Endocrinologia Rio de JaneiroRJ Brasil Divisão de Endocrinologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro Hospital Universitário Clementino Fraga Filho Divisão de Hepatologia Rio de JaneiroRJ Brasil Divisão de Hepatologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Arch Endocrinol Metab. 2024 Aug 9;68:e230477. doi: 10.20945/2359-4292-2023-0477. eCollection 2024.
To evaluate the association between subclinical hypothyroidism and hepatic steatosis and fibrosis using the noninvasive diagnostic methods transient hepatic elastography (TE) and controlled attenuation parameter (CAP) in patients with subclinical hypothyroidism.
This was a cross-sectional study including women with confirmed spontaneous subclinical hypothyroidism and an age- and body mass index (BMI)-matched control group without thyroid disease or circulating antithyroperoxidase (anti-TPO) antibodies. Exclusion criteria were age > 65 years, thyroid-stimulating hormone (TSH) > 10.0 mIUI/L, BMI ≥ 35 kg/m, diabetes, or other chronic liver diseases. Liver stiffness was classified according to TE values (in kPa) and ranged from absence of fibrosis (F0) to advanced fibrosis (F3). Hepatic steatosis was classified according to CAP values (in dB/m) and ranged from low-grade (S1) to advanced (S3) steatosis.
Of 68 women enrolled, 27 were included in the subclinical hypothyroidism group and 41 in the control group. Advanced steatosis (S3) was more frequent in the subclinical hypothyroidism group (25.9% 7.3%, respectively, p = 0.034). Circulating anti-TPO was an independent factor associated with advanced steatosis (odds ratio 9.5, 95% confidence interval 1.3-68.3). In multiple linear regression analysis, TE values (which evaluated fibrosis) correlated negatively with free thyroxine levels.
The results of this study strengthen the hypothesis that hepatic steatosis is associated with autoimmune (positive anti-TPO) subclinical hypothyroidism, independently from BMI. However, subclinical hypothyroidism alone does not appear to be associated with a significantly increased risk of hepatic fibrosis.
使用非侵入性诊断方法瞬时肝脏弹性成像(TE)和受控衰减参数(CAP)评估亚临床甲状腺功能减退症患者亚临床甲状腺功能减退症与肝脂肪变性和纤维化之间的关联。
这是一项横断面研究,包括确诊为自发性亚临床甲状腺功能减退症的女性和年龄及体重指数(BMI)匹配的无甲状腺疾病或循环抗甲状腺过氧化物酶(anti-TPO)抗体的对照组。排除标准为年龄>65 岁、促甲状腺激素(TSH)>10.0 mIU/L、BMI≥35 kg/m、糖尿病或其他慢性肝病。根据 TE 值(kPa)对肝硬度进行分类,范围从无纤维化(F0)到进展性纤维化(F3)。根据 CAP 值(dB/m)对肝脂肪变性进行分类,范围从轻度(S1)到进展性(S3)脂肪变性。
在纳入的 68 名女性中,27 名纳入亚临床甲状腺功能减退症组,41 名纳入对照组。亚临床甲状腺功能减退症组中更常见进展性脂肪变性(S3)(25.9% 比 7.3%,p=0.034)。循环抗-TPO 是与进展性脂肪变性相关的独立因素(比值比 9.5,95%置信区间 1.3-68.3)。在多元线性回归分析中,评估纤维化的 TE 值与游离甲状腺素水平呈负相关。
本研究结果进一步支持了这样的假设,即肝脂肪变性与自身免疫性(抗-TPO 阳性)亚临床甲状腺功能减退症相关,与 BMI 无关。然而,亚临床甲状腺功能减退症本身似乎与肝纤维化的风险增加无显著相关性。